Regeneron Downgraded To Neutral From Outperform At Baird By: TalkMarkets February 26, 2020 at 06:10 AM EST Baird analyst Brian Skorney downgraded Regeneron Pharmaceuticals to Neutral from Outperform with an unchanged price target of $410. Read More >> Related Stocks: Novartis Ag ADR Regeneron Pharmaceuticals